A5057323309- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diet and metabolism studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmacology and Obesity Treatment
- Adipose Tissue and Metabolism
- Heart Rate Variability and Autonomic Control
- Muscle metabolism and nutrition
- Cardiovascular Syncope and Autonomic Disorders
- Cancer, Lipids, and Metabolism
- Dietary Effects on Health
- Regulation of Appetite and Obesity
- Cancer Risks and Factors
- Diet, Metabolism, and Disease
- Adrenal and Paraganglionic Tumors
- Cardiovascular and exercise physiology
- Liver Disease Diagnosis and Treatment
- Cardiovascular Function and Risk Factors
- Biochemical Analysis and Sensing Techniques
- Adipokines, Inflammation, and Metabolic Diseases
- Circadian rhythm and melatonin
University of Perugia
2016-2025
Toronto General Hospital
2022
Ospedale Santa Maria
2017
University for Foreigners Perugia
2016
Mayo Clinic in Florida
1986-2015
Newcastle upon Tyne Hospital
2014
Brampton Civic Hospital
2014
Oregon Medical Research Center
2014
Bridgewater College
2014
Office of Naval Research
2014
To compare the pharmacokinetics/dynamics of long-acting insulin analog glargine with NPH, ultralente, and continuous subcutaneous (SC) infusion lispro (continuous [CSII]), 20 C-peptide-negative type 1 diabetic patients were studied on four occasions during an isoglycemic 24-h clamp. Patients received SC injection either 0.3 U/kg or NPH (random sequence, crossover design). On two subsequent occasions, they ultralente (0.3 U/kg) CSII U x kg(-1) 24 h(-1)) After CSII, intravenous (IV) was...
To evaluate the roles of counterregulatory hormones and insulin antibodies in impairment plasma glucose recovery from hypoglycemia diabetes mellitus, to assess relationship between glucagon response duration disease, 21 insulin-dependent diabetic patients 10 nondiabetic subjects were studied. The diabetics consisted 5 with recent onset (< 1 mo); 11 2.6 ± 0.3 (mean SEM) yr diabetes, whom had antibodies; long-term (21 3 yr), antibodies, autonomic neuropathy. During insulin-induced (28...
OBJECTIVE To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with 100 (Gla-100) in people type 2 diabetes on basal (≥42 units/day) plus mealtime insulin. RESEARCH DESIGN AND METHODS EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group study. Adults glycated hemoglobin A1c (HbA1c) 7.0–10.0% (53–86 mmol/mol) were randomized to Gla-300 or Gla-100 once daily dose titration seeking fasting plasma glucose 4.4–5.6 mmol/L. Primary end point...
Aims To compare the efficacy and safety of new insulin glargine 300 U/ml ( Gla‐300 ) with that 100 Gla‐100 in insulin‐naïve people type 2 diabetes using oral glucose‐lowering drugs. Methods The EDITION 3 study was a multicentre, open‐label, parallel‐group study. Participants were randomized to or once daily for 6 months, discontinuing sulphonylureas glinides, dose titration aimed at achieving pre‐breakfast plasma glucose concentrations 4.4–5.6 mmol/l (80–100 mg/dl). primary endpoint change...
OBJECTIVE Insulin therapy in type 1 diabetes still provides suboptimal outcomes. glargine 300 units/mL (Gla-300), with a flatter pharmacodynamic profile compared insulin 100 (Gla-100), is an approach to this problem. RESEARCH DESIGN AND METHODS People diabetes, using mealtime and basal regimen, were randomized open-label Gla-300 or Gla-100 morning evening injection, continuing the analog, followed for 6 months. RESULTS Participants (n = 549) mean age of 47 years had duration 21 BMI 27.6...
OBJECTIVE To compare insulin glargine 300 units/mL (Gla-300) versus degludec 100 (IDeg-100) in this first head-to-head randomized controlled trial. RESEARCH DESIGN AND METHODS BRIGHT (NCT02738151) was a multicenter, open-label, active-controlled, two-arm, parallel-group, 24-week, noninferiority study insulin-naive patients with uncontrolled type 2 diabetes. Participants were 1:1 to evening dosing Gla-300 (N = 466) or IDeg-100 463), titrated fasting self-monitored plasma glucose of 80–100...
Abstract Aims The goal of the study was to determine whether continuous subcutaneous insulin infusion (CSII) differs from a multiple daily injection (MDI) regimen based on neutral protamine hagedorn (NPH) as basal with respect glycaemic control and quality life in people Type 1 diabetes. Methods 5‐Nations trial randomized, controlled, crossover conducted 11 European centres. Two hundred seventy‐two patients were treated CSII or MDI during 2‐month run‐in period followed by 6‐month treatment...
The dawn phenomenon is a condition recently described in patients with insulin-dependent diabetes mellitus (IDDM) that characterized by abrupt increases fasting levels of plasma glucose or insulin requirements both between 5 and 9 a.m., the absence antecedent hypoglycemia. To determine its potential clinical relevance, we assessed frequency reproducibility 20 IDDM 13 non-insulin-dependent (NIDDM) during overnight closed-loop (feedback-controlled) intravenous infusion. After 6 increased...
A lack of appropriate autonomic warning symptoms before the development neuroglycopenia occurs frequently in patients with diabetes mellitus. The pathogenesis this phenomenon is unclear, but it associated intensive insulin therapy, prolonged duration diabetes, frequent episodes hypoglycemia, and impaired glucose counterregulation. Recently, has been proposed that repeated hypoglycemia may themselves induce phenomenon.
OBJECTIVE—To compare pharmacokinetics and pharmacodynamics of insulin analogs glargine detemir, 24 subjects with type 1 diabetes (aged 38 ± 10 years, BMI 22.4 1.6 kg/m2, A1C 7.2 0.7%) were studied after a 2-week treatment either or detemir once daily (randomized, double-blind, crossover study). RESEARCH DESIGN AND METHODS—Plasma glucose was clamped at 100 mg/dl for h subcutaneous injection 0.35 unit/kg. The primary end point action (time which plasma >150 mg/dl). RESULTS—With...
To establish the antihyperglycemic mechanisms of metformin in non-insulin-dependent diabetes mellitus (NIDDM) independently long-term, aspecific effects removal glucotoxicity, 21 NIDDM subjects (14 obese, 7 nonobese) were studied on two separate occasions, with an isoglycemic (plasma glucose ∼9 mM) hyperinsulinemic (two-step insulin infusion, 2 h each, at rate 4 and 40 mU · m−2 min−1) clamp combined [3−3H]glucose infusion indirect calorimetry, after administration either (500 mg per os, –5...
The early-morning increase in insulin requirements of patients with insulin-dependent diabetes mellitus (IDDM) has been referred to as the "dawn phenomenon." To determine roles growth hormone levels and sympathoadrenal activity this phenomenon, we studied six subjects IDDM on four occasions during a constant overnight infusion insulin. In control experiments (infusion alone), plasma glucose increased from 98 +/- 5 mg per deciliter at midnight 225 36 8:00 a.m. (P less than 0.001), production...
Accumulating evidence indicates that ghrelin plays a role in regulating food intake and energy homeostasis. In normal subjects, circulating concentrations decrease after meal ingestion increase progressively before meals. At present, it is not clear whether nutrients suppress the plasma concentration directly or indirectly by stimulating insulin secretion. To test hypothesis regulates postprandial humans, we compared effects of on levels six C-peptide-negative subjects with type 1 diabetes...
We assessed glucose counterregulation during intensive insulin therapy in 20 patients with insulin-dependent diabetes mellitus (IDDM) by injecting therapeutic doses of regular subcutaneously after overnight maintenance euglycemia. As compared nondiabetic controls matched for age and weight, 17 the had more severe prolonged hypoglycemia (nadir, 42 +/- 2 vs. 60 mg per deciliter P less than 0.01; duration, 6.2 0.4 vs 2.1 0.6 hours, 0.01). Most decreased responses several counterregulatory...
Abstract Aims To assess the efficacy and safety of one‐ two‐step dose‐increase regimens lixisenatide once daily in participants with Type 2 diabetes mellitus insufficiently controlled metformin. Methods This was a randomized, double‐blind, placebo‐controlled, parallel‐group, multi‐centre study enrolling ( n = 484) treated Participants were randomized to receive either one‐step dose increase or vs. placebo for 24 weeks, followed by ≥ 52‐week variable double blind period. Primary outcome HbA...